Journal
CANCER LETTERS
Volume 385, Issue -, Pages 51-54Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.11.008
Keywords
EGFR; EAI045; TKI; AZD9291; Rociletinib
Categories
Funding
- National Natural Science Foundation of China [81101726]
- CAHON Young Investigator Award
Ask authors/readers for more resources
The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). However, resistance develops rapidly. EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors. The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors. This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available